


Life Sciences

in the Berlin-Brandenburg Capital Region

THE GERMAN CAPITAL REGION
MORE VALUE FOR YOUR INVESTMENT



- 1 The Berlin-Brandenburg Life Science Region
- 2|3 Research Location
- 4|5 Cancer
- 6|7 Cardiovascular Diseases
- 8|9 Immunology and Inflammation
- 10|11 Nutrition-related Diseases
- 12|13 Life Science Map
- 14|15 Linking Science and Business
- 16|17 Pharmaceutical Industry
- 18|19 Clinical Research, Hospitals and Healthcare
- 20|21 Production Site
- 22|23 Facts and Figures
 - 24 A Great Place to Live
 - 25 Contacts | Imprint



Advantages of the Berlin-Brandenburg Life Science Region

- Highest concentration of research institutes in Europe
- International standing as a leading location for science
- Europe's largest university hospital
- Outstanding infrastructure
- Highly qualified workforce
- Significant political support
- Excellent production conditions
- High quality of life
- Low cost of living
- Synergies via well-established network structures



Berlin's new city center at Potsdamer Platz lit up at night

Europe's Leading Life Science Region

Clear strategic advantages in Berlin-Brandenburg

Berlin-Brandenburg is a leading location for life sciences in Europe and the world. This high-performance region at the very heart of Europe outshines its international competitors with clear strategic advantages: Berlin-Brandenburg's unique scientific landscape and strategic linkage of science, clinical research, healthcare and the economy lead to maximum research output and quick conversion into innovative products. This effective process is facilitated by the presence of Europe's largest university hospital, Charité University Medicine Berlin, as well as 370 pharmaceutical, biotech and medtech companies and over 100 non-university research institutes. Significant political

support encourages the ongoing development of key factors such as the region's outstanding infrastructure, the availability of low-cost office and commercial space and the creation of ideal conditions for research, development and manufacturing. Seven universities and 21 universities of applied sciences and technical colleges train the region's highly qualified workforce. At the same time, the captivating German capital region also acts as a magnet for internationally renowned scientists and experienced managers from all over the world. No other region offers such a range of diversity combined with a high standard yet low cost of living. www.lifescience-bb.de

Biotech and medtech companies.....	350
Pharmaceutical companies.....	20
Universities.....	7
Universities of applied sciences and technical colleges.....	21



Research lab at Bayer Schering Pharma

Europe's Leading Research Location

Science as the driving force of value creation

In the past several years, Berlin-Brandenburg has emerged as the most important location for science in Europe. Nowhere else can you find such a high density and superior quality of research institutes. Distinct synergies result from intensive collaboration among the life sciences as well as the integration of key technologies from other disciplines such as information technology, nanotechnology, optics and microsystems engineering. Expenditures on research and development in Berlin are equal to four percent of the state's gross domestic product and thus far

above the federal average in Germany. Berlin is rated second on the European innovation index. The Berlin-Brandenburg region's unique concentration and linkage of research, science, clinical research, healthcare and the economy not only leads to maximum performance in research, but also to the successful implementation of that research into innovative products. Over 350 regional companies in the fields of biotechnology and medical technology are involved in this unique process.

Internationally renowned research location

Universities	7
Universities of applied sciences and technical colleges	21
More than 100 non-university research institutes, including:	
Institutes of the Max Planck Society	8
Archive of the Max Planck Society	1
Institutes of the Hermann von Helmholtz Association	7
Institutes of the Leibniz Society	19
Branch Institutes of the Leibniz Society	2
Institutes of the Fraunhofer Society	10

Efficient technology transfer

Successful spin-off companies emerging from universities and research institutes

- Analyticon Discovery
- Berlin Heart
- Biotronik
- Celon (Olympus Medical Group)
- Combinature Biopharm
- Eckert & Ziegler
- Epigenomics
- GenPat77 Pharmacogenetics
- Jerini
- MagForce
- metanomics
- Mologen
- Noxxon
- Scienion
- Siegfried Biologics

Science-based Industry as a Key Economic Factor

Professor Stock, what characterizes Berlin-Brandenburg as a research location?

Berlin has been setting worldwide standards in science ever since the age of Nobel Prize winners such as Emil von Behring, Robert Koch, Max Planck and Albert Einstein. We have an unusually high concentration of excellent research institutes, which allows us to take up a leading position in Europe. The potential here is enormous, especially with top research facilities such as the Max Planck Institutes, Helmholtz Institutes and Fraunhofer Institutes as well as the major universities and technical colleges. Over 85,000 people work here in science and research. The region's outstanding international reputation continues to attract foreign students and young scientists. In fact, approximately 25,000 of the region's 180,000 university-level students come from abroad.

»In the Berlin-Brandenburg region, you'll find all the elements of a value chain in the field of biomedicine. This distinguishes the region from all other locations.«

What role do science and research play in the Berlin-Brandenburg economy?

Culture and science are the capital region's major strengths. We place uncompromising emphasis on the region's science-based industry. Projects initiated in the 1990s have already started bearing fruit. Some of the region's most notable success stories involve innovative industrial products developed in the fields of biotechnology and medical technology. In the Berlin-Brandenburg region, you'll find all the elements of a value chain in the field of biomedicine, ranging from basic research all the way to young, technology-oriented companies and major manufacturers. This distinguishes the region from all other locations.



Prof. Dr. h.c. Günter Stock
President of the Berlin-Brandenburg Academy of Sciences and Humanities
www.bbaw.de

How would you rate the political support provided in this field?

Politicians realized the potential in the field early on and acted quickly and decisively. The »Berlin-Brandenburg Healthcare Region« master plan initiated by the states of Berlin and Brandenburg combines the commitment of the two states to the goal of using the region's unique potential as effectively as possible. A professional form of cluster management was introduced to advance the strategic development of the region as a leading location for life sciences.

What role does the Berlin-Brandenburg Academy of Sciences and Humanities play in this scenario?

Important representatives from all scientific disciplines are active at our academy. We see ourselves as an institute responsible for supporting an interdisciplinary and supra-regional dialogue between the relevant players. Our central role is to promote the creation of networks that serve to ensure that knowledge, research and teaching continue to prosper in the Berlin-Brandenburg region.

What role does culture play in the Berlin-Brandenburg science community?

The great metropolitan cities of the world are all known for their ability to create and sustain a reasonable symbiosis between politics, culture, science and industry. For many scientists, culture is a special source of inspiration. Berlin fulfills this criteria in an exemplary manner.




From left to right

New offices of the Fraunhofer Institute for Biomedical Technology (IBMT) at the Potsdam-Golm Science Park

Leibniz Institute for Molecular Pharmacology (FMP) in Berlin-Buch boasts a 900 MHz spectrometer

Max Delbrück Communications Center in Berlin-Buch



Implantation of low-level radioactive iodine seeds from Eckert & Ziegler in the prostate

A Leading Position in Oncology

Sophisticated research, ground-breaking diagnostic technologies, innovative therapies

The Berlin-Brandenburg life science and healthcare community regularly achieves cutting-edge results in oncology. Its ultimate goal is to gain an improved understanding of tumor diseases and the methods with which they can be fought effectively. The Charité Hospital, the Max Delbrück Center for Molecular Medicine (MDC) and the Max Planck Institute for Molecular Genetics (MPI-MG) are only three examples of the region's outstanding expertise in oncology. Twenty-nine research groups are active in the

MDC's research program alone. The MPI-MG coordinates a cancer-oriented European network for systems biology (ESBIC-D). A number of biotech and medtech companies are working on new therapy concepts. Groundbreaking proton technology now used in the treatment of eye tumors was developed at the Hahn Meitner Institute and has set new international standards. Bayer Schering Pharma is recording significant growth rates in cancer medications and also boasts an extensive development pipeline.

Leading Cancer Research

- Berlin Cancer Net in the National Genome Research Network
- Competence Network Paediatric Oncology and Haematology (KPOH), Coordination Group
- Competence Network Acute and Chronic Leukaemia
- Transregio-SFB Collaborative Research Initiative »Principles and Applications of Adoptive T Cell Therapy«
- Joint Research Project »Molecular Mechanisms in Malignant Lymphoma« funded by German Cancer Aid (Deutsche Krebshilfe)
- Center for »Hereditary Breast Cancer« funded by German Cancer Aid (Deutsche Krebshilfe)
- UICC Telepathology Consulting Center at Charité Hospital

Product innovations from Berlin-Brandenburg

- Biochips for cancer diagnostics from Scienion, Invitek and Signature Diagnostics
- Magnetic nano-particle thermotherapy from MagForce
- Radio-frequency thermotherapy from Celon
- Innovative cancer diagnostics using DNA methylation from Epigenomics
- Proton therapy at the Hahn Meitner Institute
- Radioactive iodine seeds from Eckert & Ziegler

Epigenomics – A Successful Technology Pioneer from Berlin

A unique approach to molecular diagnostics

Epigenomics was founded in 1998 as a spin-off of the Max Planck Institute for Molecular Genetics. It quickly established itself as a leading molecular diagnostics company specializing in innovative DNA methylation technology for the early diagnosis and prognosis of diseases. DNA methylation is a natural process of gene regulation by which genes are switched on and off. Cancer diagnosis is at the very center of Epigenomics' business activities. Christian Piepenbrock, the company's co-founder and COO, is committed to Berlin: »We enjoy ideal conditions for innovative research here. Today, we are a transatlantic company with headquarters in Berlin and a subsidiary in Seattle.«

»Our most critical advantage is that we're able to attract high-ranking managers to Berlin. They feel at home in the exciting and dynamic capital city.«


Cutting-edge Technology: Cooperation with major players in the pharmaceutical and diagnostics industry

Epigenomics develops blood-based diagnostic tests for the early recognition of common cancers such as colon, prostate and breast cancer. The company also cooperates in the development of tissue-based tests that allow for individualized patient prognoses, for example with respect to the therapeutic success of specific medications. Among the development partners currently using Epigenomics' innovative approach to the discovery and validation of biomarkers are Pfizer, AstraZeneca, Wyeth, Biogen Idec, Johnson & Johnson and Philip Morris. Epigenomics has also developed an international network of academic partners that includes such prominent institutions as the Sanger Centre in Cambridge, UK, Johns Hopkins University in Baltimore, Maryland, Charité University Hospital in Berlin and the Mayo Clinic in Rochester, Minnesota.


The management team at Epigenomics, in addition to the company's proprietary technology and its significant market potential, has impressed not only the pharmaceutical industry but also the financial world as well. Since its founding in 1998, the company has received over 100 million euro from international investors. Epigenomics went public in 2004. »Investors enjoy coming to Berlin,« explains Piepenbrock, »but our most critical advantage here is that we're able to attract high-ranking managers to Berlin. They feel at home in the exciting and dynamic capital city.«



Christian Piepenbrock
COO Epigenomics AG
www.epigenomics.de



From left to right
Iodine seeds from Eckert & Ziegler in Berlin-Buch are delivered in radiation-safe containers
Celon, a subsidiary of Olympus in Teltow
Biochip for the diagnosis of cancer from Epigenomics



Stent production at Biotronik

Innovative Treatment of Cardiovascular Diseases

Research findings flow directly into practical applications

Heart patients from all over the world come to Berlin for treatment. Based on its excellent basic research, translational medicine and first-class clinical care for cardiovascular and circulatory disease, Berlin established itself already in the 1960s as an internationally prominent center in the field. Its outstanding reputation is carried first and foremost by the German Heart Institute Berlin (DHZB) and the Charité Hospital. The DHZB boasts Germany's largest heart transplantation program. Additionally, the DHZB and its offshoot, Berlin Heart, are international

leaders in the development of artificial hearts. Several medical technology companies from Berlin and Brandenburg profit from their cooperation with clinical institutes. Berlin-Chemie obtains approximately 40% of its sales from cardiovascular medication. Bayer Schering Pharma and Siemens have combined their expertise to research a new computer tomography technology in connection with x-ray contrast media that promises diagnostic advantages for heart physicals.

German Heart Center Berlin

Open heart surgeries (total)	55,000
Open heart surgeries (annual)	3,000
Other heart and cardiovascular operations (annual)	2,000
Open heart surgeries in newborns, infants, children (annual)	450
Heart transplants, of which 140 were performed on children (total)	1,500
Heart and lung transplants (total)	380
Artificial heart implants (total)	960

Charité

- Charité Center for Cardiovascular Medicine
- Franz Volhard Clinic
- Charité Center for Cardiovascular Research
- Cardiovascular Network of the National Genome Research Network
- Competence Network Heart Failure
- SFB Inflammatory Cardiomyopathy
- Geneheart, Genomics of Cardiomyocyte Signalling to treat and prevent heart failure
- Cardiovascular, cellular and molecular mechanisms of cardiovascular diseases (Training Program)

Berlin-Brandenburg – A Motor for Cardiological Innovation

Wide-ranging expertise

The entire life science community in the capital region boasts extensive and complementary expertise in the field of cardiovascular medicine, whether it be research, clinical applications or product innovations. As a result, heart patients from all over the world choose to undergo treatment in Berlin. High-quality products made in Berlin-Brandenburg also continue to be in high demand in the rest of the world. Regional leaders in the field of cardiovascular research include such institutions as the German Heart Center Berlin, the Charité and the Max Delbrück Center for Molecular Medicine (MDC). The MDC is home to the »Cardiovascular, Circulatory and Metabolic Diseases« program which forms part of the healthcare research activities of the Helmholtz Society. The integrative and interdisciplinary approach taken by the Center for Cardiovascular Research (CCR) at the Charité is unique in the field of cardiovascular research in Germany. Twelve working groups with a staff of over 100 from various disciplines collaborate on different projects. Two offshoots of the Charité are at the cutting-edge in the field of cardiovascular tissue engineering: Autotissue and Vasotissue develop individual implants such as heart valves and vascular prostheses on the basis of human cells.

»The keys to our success are all found in Berlin. They include a concentrated network of first-class clinics and prominent research institutes.«

International market leaders – cardiological medtech products from Berlin-Brandenburg

Approximately one-half of the sales produced by Berlin's internationally successful medical engineering companies are made up of implants and prostheses. Products from the field of cardiovascular systems account for 84% of the products in this group.



Christoph Böhmer
Managing Director Biotronik GmbH & Co. KG
www.biotronik.com

Pacemakers, heart support systems, defibrillators and stents – high-quality products from Berlin-Brandenburg are very much in demand on the world stage. The most successful company in the field is Biotronik, a worldwide leading producer of cardiological implants. Constant innovation is the trademark of this successful, 40 year-old company all the way from their production of the first German pacemaker to the trend-setting development of their Home Monitoring Systems. Today, Biotronik employs a worldwide workforce of over 3000, 1200 of which are active at the company's headquarters in Berlin-Neukölln. »The keys to our success are all found in Berlin,« explains managing director Christoph Böhmer. »They include a concentrated network of first-class clinics and prominent research institutes. Access to this know-how is just one of many important advantages of our location. Berlin also offers our employees an inspiring work environment. These basic conditions make it easy for us to find employees with the key qualifications we need to support our ongoing growth.«

»Berlin also offers our employees an inspiring work environment.«



From left to right
Production at Berlin-Chemie in Berlin-Adlershof
Biomarker development for chronic heart failure at BRAHMS in Hennigsdorf
SeQuent PTCA® balloon catheter from B. Braun Melsungen in Berlin



High throughput screening of drug candidates in a bioassay at Revotar

Insights into the Immune System

Closely integrated research, new diagnostics

World-renowned Berlin research institutes such as the Max Planck Institute for Infection Biology, the German Rheumatism Research Center, the Robert Koch Institute and the Charité represent outstanding achievements in immunology, molecular biology and cutting edge research into infection processes. Immunological research is also one of the pillars of the new Berlin-Brandenburg Center for Regenerative Therapies (BCRT). Regional companies active in related fields benefit from cutting-edge research findings and cooperative ventures. For example,

an innovative medication from the Berlin company Jerini for the treatment of various inflammatory diseases is set to receive its initial approval. Bayer Schering Pharma has already set worldwide standards for the treatment of multiple sclerosis and is currently developing a new class of anti-inflammatory substances together with AstraZeneca. Diagnostic companies such as BRAHMS and Invent are developing innovative tests for the diagnosis of autoimmune and inflammatory diseases.

Leading Research Projects and Networks

- Infection Genome Network at the National Genome Research Network
- European Center for Allergy Research (ECARF)
- GA²LEN, Global Allergy and Asthma European Network
- RISET, Reprogramming the immune system for the establishment of tolerance
- AUTOCURE, Post genomic approaches for inflammatory rheumatic diseases
- CELLAID, Curative cell therapies for autoimmune diseases
- SIPAGE – Chronic Inflammation at the National Genome Research Network
- SFB 421 »Protective and pathological consequences of antigen-processing«
- SFB 633 »Induction and modulation of T cell-related immune reactions in the gastrointestinal tract«
- SFB 650 »Cellular approaches to the suppression of unwanted immune reactions – from bench to bedside«
- Berlin Brandenburg Center for Regenerative Therapies
- Competence Network Systemic Inflammatory Rheumatic Disease
- ZIBI – Interdisciplinary Center for Infectious Biology and Immunology

BRAHMS Diagnostics – A Market Leader from Brandenburg

Providing the world with high-quality products from Hennigsdorf

BRAHMS has always blazed a trail of its own ever since its creation in 1994. It was the first company in the pharmaceutical industry to emerge from a management buy-out. Each one of the founding members that took over the diagnostics company from Henning Berlin/Marion Merrell Dow is still on the executive team today. After five years, the fast-growing company moved to its current location at the newly founded Hennigsdorf Biotech Center.

»In Hennigsdorf we enjoy an optimal infrastructure for our business. We also profit immensely from close contacts to the park management and local authorities,« explains Dr. Bernd Wegener, CEO of BRAHMS AG and Chairman of the German Pharmaceutical Manufacturers Association (BPI). »The significant political support we receive also facilitates our work.« Today, the internationally successful company has a total of approximately 320 employees, 200 of which work at its headquarters in Hennigsdorf. The company's product range includes more than 60 innovative in-vitro diagnostics and lab analysis systems designed for the carrying out of immunoassays.

»In Hennigsdorf we enjoy an optimal infrastructure for our business. We also profit immensely from close contacts to the park management and local authorities«

BRAHMS diagnostics make therapy decisions easier


In addition to its strong position in the field of thyroid diagnostics, BRAHMS is also active in the fields of sepsis, tumor diseases, fertility and prenatal diagnostics. The search for new biomarkers plays a central role. One to two patents are registered every month. Brahms has developed, for example, the world's first test with which a sepsis – the most common cause of death in intensive care units – can be detected within one hour. The test for the biomarker Procalcitonin (PCT) provides rapid and reliable information as to whether a bacterial or viral infection is present – an important criteria when choosing the

appropriate form of treatment. Growth rates of approximately 45% testify to the test's unique attraction. »Inflammatory and autoimmune diseases are fields of central importance,« explains Wegener. »We take advantage of the region's outstanding expertise by cooperating regularly with the Max Planck Institute for Infection Biology, collaborating with the University of Potsdam for the development of measuring systems, and working with the Charité Hospital for the clinical validation of our tests.« At the moment, BRAHMS is developing new, ultra-sensitive tests for use in hospital emergency wards. These tests are designed to provide absolute clarity as to whether a heart or lung infection is present and also when determining a patient's prognosis.


»We take advantage of the region's outstanding expertise by cooperating with the Max Planck Institute for Infection Biology, the University of Potsdam and the Charité.«



Dr. Bernd Wegener
CEO BRAHMS AG
www.brahms.de



From left to right
Research lab at Jerini in Berlin-Mitte
Research lab at Revotar in Hennigsdorf
BRAHMS headquarters in Hennigsdorf



Well-known throughout the world: Plant genome research at the Max Planck Institute for Molecular Plant Physiology

Research into Nutrition-related Diseases

Bringing together regional technologies and expertise

Berlin-Brandenburg boasts a considerably high level of expertise in the field of nutrigenomic research. Regional experts combine their resources to perform in-depth research into nutrition-related diseases and develop innovative products for prevention, diagnostics and therapy. The German Institute for Human Nutrition (DIfE) brings together clinical nutrition research with classical nutrition science in a way that is unique in Germany. Among the

many internationally prominent research institutes in the field of genome research are the Max Planck Institute for Molecular Plant Physiology and the Max Planck Institute for Molecular Genetics. The Bayer subsidiary Bayer Bioscience and the BASF offshoot metanomics are just two of the many regional companies successfully engaged in the field of functional genome research on plants and their practical application.

BioProfile Nutrigenomics Network

- 24 Projects
- 60 member companies and working groups from research institutes, universities and colleges
- Total funding of 27 million euro
- Fields of research: obesity/metabolic syndrome, cancer, allergies, cardiovascular diseases

Regional companies in the BioProfile Nutrigenomics Network

- Agowa
- Analyticon Discovery
- Biotecon Diagnostics
- Congen
- Celltrend
- Epo
- Glycotope
- Invent Diagnostica
- Jerini
- metanomics
- MicroDiscovery
- Proteome Factory
- Scienion
- Signature Diagnostics

Leading research projects and networks

- Berlin-Brandenburg Nutrigenomics Network
- CFFG, Center for Functional Genomics
- GABI Network, Genome analysis in biological plant systems
- GoFORSYS, Center for Systems Biology
- EPIC Study (European Prospective Investigation into Cancer and Nutrition)

BioProfile Nutrigenomics – Leading in New Developments

Berlin-Brandenburg sets the pace

In 2001, the Berlin-Brandenburg region was one of the winning candidates in the German Federal Ministry for Education and Research's BioProfile competition for their project entitled »Genomics and phyto biotechnology for the diagnosis, prevention and treatment of nutrition-related diseases.« Up to 18 million euro prorated subsidies have been made available to 24 ambitious federation projects. The results of academic research are transferred effectively into application-oriented projects and products. BioProfile projects include innovative approaches throughout the entire value chain.

»For this type of research and development in particular, the Berlin-Brandenburg region offers an ideal scientific and technical landscape that is unique in the world.«

Taking Aim at Obesity and Obesity-related Diseases

One of BioProfile's main focuses is the connection between obesity, diabetes and the metabolic syndrome. The Max Planck Institute for Molecular Genetics identifies and characterizes specific genes relevant to obesity. At the German Institute for Human Nutrition, analysis is performed on new targets to prevent and treat adiposity. MicroDiscovery uses bioinformatics to explore connections between obesity and diabetes using an in silico model. The Adiposity-Chip from Sciencion provides information about molecular-genetic connection between obesity and obesity-related illnesses. Noxxon develops innovative active substances, so-called Spiegelmers, for the treatment of obesity. This new innovative Spiegelmer technology has also impressed global companies such as Pfizer, which has secured the licence for one of Noxxon's most promising product candidates and is cooperating with Noxxon on the development of further Spiegelmer products.

Metanomics, a subsidiary of BASF, is currently using its broad metabolic analysis technology – a proprietary method called Metabolite Profiling – to develop new insights, differentiated and early diagnoses, and products for nutrition-related diseases such as Type 2 diabetes and obesity. For Dr. Arno Krotzky, CEO of metanomics GmbH and metanomics Health GmbH, regional expertise plays an important role: »For this type of research and development in particular, the Berlin-Brandenburg region offers an ideal scientific and technical landscape that is unique in the world. It excels in the fields of plant biotechnology, applied clinical research, nutritional research and bioinformatics. These fields work together cooperatively and are partly supported additionally by the BioProfile Nutrigenomics Network. For years now, metanomics has taken advantage of this outstanding environment and has enjoyed great success in joint projects with the Max Planck Institute for Molecular Plant Physiology in Golm, with the various clinics of the Charité Hospital in Berlin, with the German Institute for Human Nutrition in Potsdam-Rehbrücke as well as with numerous other institutes and companies.«








Dr. Arno Krotzky
CEO metanomics GmbH und metanomics Health GmbH
www.metanomics.de




From left to right
The German Institute for Human Nutrition in Potsdam-Rehbrücke (DIfE)
The metanomics greenhouse in Berlin-Charlottenburg
Software by MicroDiscovery at work

Life Science Cluster Berlin-Brandenburg


Select locations

-  Hospitals
-  Life Science Companies
-  Pharmaceutical Companies
-  Research Institutes
-  Universities and Colleges



- | | |
|--|--|
| <ul style="list-style-type: none"> 1 ATB - Institute for Agricultural Engineering Bornim 2 BIOPOS Research Institute for Bioactive Polymer Systems 3 Charité – University Medicine Berlin 4 German Heart Institute Berlin 5 German Institute for Human Nutrition in Potsdam-Rehbrücke (DIFE) 6 German Rheumatism Research Center Berlin 7 Fraunhofer Institute for Applied Polymer Research 8 Fraunhofer Institute for Applied Polymer Research – AG Chromogen Polymers 9 Fraunhofer Institute for Biomedical Engineering – Molecular Bioanalytics & Bioelectronics 10 GKSS Research Center – Institute for Polymer Research 11 Konrad Zuse Center for Scientific Computing Berlin 12 Leibniz Institute for Catalysis 13 Leibniz Institute for Molecular Pharmacology (FMP) | <ul style="list-style-type: none"> 14 Max Delbrück Center for Molecular Medicine (MDC) 15 Max Planck Institute for Infection Biology 16 Max Planck Institute of Colloids and Interfaces 17 Max Planck Institute for Molecular Genetics 18 Max Planck Institute for Molecular Plant Physiology 19 Robert Koch Institute |
|--|--|



B | BRAUN
SHARING EXPERTISE

BERLIN-CHEMIE
MENARINI

Berlin Heart

bernafon[®]
Innovative Hearing Solutions

LGC

Setting standards
in analytical science

Jerini

merete[®]
GERMAN ENGINEERING FOR LIFE

Bayer HealthCare
Bayer Schering Pharma

MOLOGEN AG

metanomics
new dimensions in discovery

MAICO

BASF
The Chemical Company


SIEMENS

SOMATEX[®]
Medical Technologies GmbH

B • R • A • H • M • S

WORLD OF MEDICINE

VANGUARD
MEDICAL SERVICES FOR EUROPE



Innovative chip technology from Scienion is applied at the BioHyTec and Nutrigenomics Research Networks

Networks Accelerate Technology Transfer

Intensive cooperation between scientific research, hospitals and industry

The high concentration of outstanding research institutes and cutting-edge achievements in the Berlin-Brandenburg region make it one of the world's leading locations for life sciences. A key factor in the region's ongoing international success is the intensive linkage and cooperation among partners working in scientific research, hospitals, clinics, business and industry. At the interface between science and business, two major regional initiatives – BioTOP Berlin-Brandenburg and TSBmedici – support a wide spectrum of networking and technology transfer in their respective fields of biotechnology and medical technology.

As a result of their excellent work, regional networks receive major financial support from the German federal government. Local medical and scientific expertise is also in high demand among national and international networks, for example at the national level in the German Competence Networks in the fields of pediatric oncology and hematology, heart failure and congenital heart disease, rheumatism, stroke, pneumonia as well as in the National Genome Research Network.

Biotech Networks

- Berlin Center for Genome Based Bioinformatics (BCB)
- BioHyTec Biohybrid Technologies Network
- Center for Functional Genomics (CFFG)
- Genome Analysis in Biological Plant Physiology (GABI)
- Network for RNA Technologies (RiNA)
- Network Glycobiotechnology Berlin-Brandenburg
- Nutrigenomics Network Berlin-Brandenburg
- Pre-symptomatic Tumor Diagnostics Network
- White Biotechnology Network
- Protein Structure Factory (PSF)
- Regenerative Medicine Initiative Berlin (RMIB)
- Ultra Structure Network (USN)
- Center for Drug Development

Medtech Networks

- Berlin NeuroImaging Center (BNIC)
- Bernstein Center for Computational Neuroscience
- Imaging Network Berlin
- Berlin and Brandenburg Optical Technologies Network (OpTecBB)
- Berlin-Brandenburg Medical Engineering Network (medtacet-BB)
- Medical Engineering Center for Miniaturized Monitoring and Intervention Systems (MOTIV)
- Musculoskeletal Research Center Berlin (MRCB)
- Network for Integrated Telemedical Systems (NEST)
- Network for Healthcare Telemedicine (TeGeNet)
- Center for Microsystems Engineering, ZEMI

The Berlin-Brandenburg Advantage – Strong Network Synergies

Bringing together interdisciplinary scientific expertise

The potential for strong synergies as a result of the close linkage of regional players in Berlin-Brandenburg was recognized and encouraged from the very beginning. »Nowhere else in Europe do you find such outstanding research and intensive cooperation between business and science,« explains Dr. Kai Bindseil, Director of BioTOP Berlin-Brandenburg. »In the field of biotechnology, Berlin's twelve networks of expertise ensure that the capital region maintains its prominent international reputation as a leader in fields such as RNA technology, bioanalysis and nutrigenomics research.«

In Berlin-Brandenburg, research findings from different fields of expertise are coordinated in an optimal manner. For example, scientific results in the fields of functional genome research on humans, animals, plants and microorganisms are brought together with proteomics, glyco-biology and the latest findings in the field of ultrastructure research. The region's many bioinformatics specialists provide state-of-the-art analysis tools and enable optimal data linkage. The Center for Functional Genomics (CFFG) alone has 53 members made up of various research institutions and companies.

»Nowhere else in Europe do you find such outstanding research and intensive cooperation between business and science.«

Strong network linkages are encouraged even further, as Bindseil explains: »These networks are now in the process of expanding to include translational development centers designed to allow the quick and coordinated flow of research findings into clinical practice and product development.« Bindseil is confident: »In the game of international biotech research and production, the capital region holds a hand full of trumps.«



Dr. Kai Bindseil
Director, BioTOP Berlin-Brandenburg
www.biotop.de

The same applies in equal measure to medical technology. The two branches engage in increasing cooperation in Berlin-Brandenburg, for example in the complex fields of biohybrid technologies, regenerative medicine and new imaging techniques. The Berlin Imaging Network coordinated by TSBmedici was founded in September 2006 with eleven partners from science and business. The network helps to coordinate work in the field of diagnostic imaging ranging from molecular imaging to the ongoing development of instrument engineering, which includes computer tomography, magnetic resonance tomography and other optical procedures. Close connections to innovative biotechnology also exist in the fields of contrast agent research and the development of new nanoparticles.

Berlin plays a leading international role in the field of telemedicine networking, for example in the European Union's GALENOS Project (Generic Advanced Low-cost Trans-European Network). Technology oriented networks such as MOTIV (Miniaturized Monitoring and Intervention Systems) and OpTecBB (Berlin-Brandenburg Optical Technologies Network) promote the integration of different key technologies in the development of innovative products. The goal of medtecnet Berlin-Brandenburg, a suppliers network, is to create even further linkage between medtech companies and their customers.




From left to right

The White Biotechnology Network is coordinated from Luckenwalde Biotech Park.

The new lab for medical genome research in Berlin-Buch

Ludwig Erhard Haus in Berlin-Charlottenburg, home of Berlin Partner, BioTOP Berlin-Brandenburg and TSBmedici



Berlin – Headquarters and research facilities of Bayer Schering Pharma

Innovative Pharmaceutical Location

Successful and versatile companies from medium-sized businesses to global players

The ongoing success of pharmaceutical companies from Berlin-Brandenburg is based on a long history of innovative products and a strong medical tradition dating back to the 19th century. The pharmaceutical industry profits from the region's outstanding scientific landscape, its renowned clinical research environment and its close proximity to the federal government. These factors apply to global players such as Bayer Schering Pharma, Berlin-Chemie (Menarini Group), ALTANA Pharma (Nycomed Group) and sanofi-aventis, but also to the region's 20 medium-sized pharma companies. The most recent example of the region's irresistible appeal is Bayer's takeover of

Schering and the settlement of the new company, Bayer Schering Pharma AG, in Berlin. Yet another success story is Berlin-Chemie AG, a subsidiary of the Italian corporation Menarini since 1992. Berlin-Chemie is currently increasing its national and international standing by means of above-average growth rates. Berlin-Brandenburg also attracts companies from abroad. The world's third largest pharma corporation, sanofi-aventis, conducts its German marketing initiatives, sales and distribution from Berlin. In Oranienburg, ALTANA Pharma (Nycomed Group) operates a state-of-the-art facility for the manufacturing of over 80 products including the blockbuster Pantoprazole.

Successful medium-sized companies in the region

• ct-Arzneimittel GmbH	Germany's fifth largest producer of generic drugs
• Haupt Pharma AG	A leading European pharmaceutical producer
• Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG	Licensing and marketing of drugs; sale of pharmaceuticals; distribution of active substances and special chemicals
• Dr. Kade Pharmazeutische Fabrik GmbH	Production and marketing of prescription drugs
• Klosterfrau Healthcare Group with Lichtwer Pharma GmbH and Divapharma-Knufinke GmbH	Natural pharma products and DTC goods
• Dr. Gerhard Mann, Chem.-pharm. Fabrik GmbH	Leading ophthalmic producer

Bayer Schering Pharma

Turnover in 2005: 9.1 billion euro*

Research budget in 2005:
1.6 billion euro*

One of the top 10 global suppliers of specialized pharmaceutical products

* Bayer and Schering pro forma combined

Business Units

- Oncology
- Hematology/Cardiology
- Women's Healthcare
- Specialized Therapeutics
- Diagnostic Imaging
- Primary Care

Bayer Schering Pharma – The Big Leagues of the Pharma Industry

Leading position in specialty pharmaceuticals

Bayer Schering Pharma in Berlin is a globally active pharmaceutical corporation that plays a major national and international role in the specialty pharmaceuticals segment. Bayer Schering Pharma is the world's market leader in hormonal contraception and holds a leading position in the fields of multiple sclerosis therapy, hematology, cardiology, oncology and contrast agents. Bayer Schering Pharma is also at the cutting edge in the field of biotechnology. As Arthur J. Higgins noted upon his official appointment as CEO of the new Bayer Schering Pharma: »Berlin is entering a new historical chapter as a center of excellence in the German pharmaceutical industry.« The turbulent takeover process of 2006 is over and now, after 155 years of independence, Berlin's Schering AG – which went from a »green apothecary« to a worldwide pharmaceutical group – has been officially taken over by Bayer and integrated into its healthcare division.

»Berlin is entering a new historical chapter as a center of excellence in the German pharmaceutical industry.«

The Berlin business location continues to excel. According to Higgins: »Berlin is an attractive location with an excellent research infrastructure.« The new Bayer Schering Pharma company can count on the optimum structures and network activities already set up by Schering in the capital region: these include cooperation agreements with regional universities, research institutes and biotech companies, joint projects with the Charité in research and clinical practice and the close proximity to federal political decision makers. Indeed, the region offers numerous contact points for ongoing key activities.

An impressive product portfolio and a promising pipeline

According to Higgins, the goal of integration is »to unite the best of both companies and to form a whole that produces more value than the sum of its parts.« The focus is clearly not on size but much more on »innovative products that address unmet medical needs.« Bayer Schering Pharma is divided into six business divisions and has a solid product pipeline. In the course of the global R&D restructuring process, Berlin will host the research fields of diagnostic imaging, oncology, gynecology and andrology. In the field of oncology in particular, the fusion of Bayer and Schering provides an opportunity to take up a leading position in terms of global competition. The stated goal of the new company is to focus on innovation and customer needs and to grow faster and stronger than the pharmaceutical market itself. The well-known Schering slogan, »Aus Berlin in alle Welt« (»From Berlin to the Whole World«) will therefore continue to reflect the significance of the company's Berlin site.



Arthur J. Higgins
CEO Bayer Schering Pharma AG
www.bayerscheringpharma.de



From left to right

ALTANA Pharma Oranienburg (Nycomed Group), a central medical production facility for solid medication forms

Bayer Schering Pharma in Berlin-Wedding

The Sony Center in Berlin is home to the marketing and sales offices of sanofi-aventis in Germany.



A microbiology lab at the Helios Clinic

Excellent Clinical Research and Healthcare

State-of-the-art medical research and healthcare

The Berlin-Brandenburg region is home to Europe's largest university hospital, Charité – University Medicine Berlin, and boasts many other cluster advantages, including a tremendous concentration of 120 hospitals and specialized clinics, a broad level of outstanding basic research, a high degree of advanced medical care, specialized expertise in individual medical fields and ideal conditions for clinical research.

The Vivantes Health Network, which represents the largest municipal hospital corporation in Germany, has its headquarters in Berlin. The privately held Helios Group operates several clinics in the region and recently moved its central offices to Berlin. Leading contract research organizations also take regular advantage of the large pool of accessible patients in the region. Parexel International, for example, currently has a workforce of over 1000 employees.

Charité – University Medicine Berlin

Berlin sites	4	DFG research groups	10
Charité Centers	17	Specialized research fields	10
Clinics and Institutes	128	New studies/year	500
In-patients/year	128,000	Spin-offs	20
Out-patients/year	1,080,000	Annual turnover in billions of euro	1
Employees	14,400	Third-party funds/year	
Students	7,500	in millions of euro	100
Graduate research groups	7		

The Charité – A Motor of Innovation with International Renown

Professor Ganten, what distinguishes Berlin-Brandenburg in particular as a leading location for hospitals and clinics?

One of the fundamental advantages is the region's large number and wide variety of research institutes. There is almost no scientific field that is not represented in our clinical practice here. The region also has a broad multidisciplinaryity that is applied more effectively than anywhere else in terms of content, methodology and institutional cooperation.

In 2003, the Charité was transformed into a major university clinic, and we enjoy optimal opportunities for collaboration with research institutes and biotech companies at all four of our locations. This unique form and concentration is unrivalled in Germany and indeed hard to find in the world.

»We're able to conduct clinical studies much faster and better than anywhere else.«

What role does translational medicine play in this scenario?

The Charité is a clinical research facility. All of our research activities are relevant to medical care. A good example of translational medicine is the Imaging Science Institute (ISI), our joint venture with Siemens. Here we perform application-oriented research into the most state-of-the-art imaging methods, and we also develop new devices and accompanying software. We also research new contrast agents – new »smart molecules« for molecular imaging and their absorption and effect in the body. Our goal is to identify new pathophysiological relations, thus facilitating early diagnosis and prevention.



Professor Dr. Detlev Ganten
Board Chairman, Charité – University Medicine Berlin
www.charite.de

What kind of economic impact does clinical research and healthcare have on Berlin-Brandenburg?

The decisive point here is the close link between healthcare, hospitals and research, and thus the innovative aspect of the location. As a major partner for clinical trials, the Charité plays a significant role in the value chain. Our status as the largest university hospital in Europe also gives us tremendous qualitative and quantitative potential. We are able to conduct clinical studies much faster and better than anywhere else. The Charité takes in approximately 30 million euro annually for therapeutic studies. Our goal is to double if not triple this number. We are moving the Charité in the direction of a commercially successful company, which is a new development in German university medicine.

In 2010, the Charité will celebrate its 300th anniversary – how does tradition influence today's operations?

As a brand name, the Charité has an excellent international reputation. Throughout the world, people are aware of the major accomplishments that German medical science performed here at the Charité, which include the achievements of Robert Koch, Emil von Behring, Paul Ehrlich and Rudolf Virchow. People enjoy being involved in this rich tradition, which makes it easy to attract very good people to Berlin. At the same time, this tradition also reflects our great obligation to maintaining these standards and values.



From left to right
Lab work at the Helios Clinic in Berlin-Buch
Main entrance and emergency center at the Ernst von Bergmann Clinic in Potsdam
Tomo Therapy system at the Charité Clinic for Therapeutic Radiology



Oranienburg - where ALTANA Pharma (Nycomed Group) produces more than 80 products in solid medication forms

Ideal Conditions for Manufacturing

An internationally competitive location with a large workforce of well-trained technical personnel

The Berlin-Brandenburg region is a very attractive production site for the chemical-pharmaceutical industry as well as for industrial medicine and biotechnology. The region boasts a large pool of educated professionals, unique and investor-friendly cooperation with public authorities, and the best subsidy opportunities available in Europe. Global players such as Altana Pharma (Nycomed Group) and BASF produce pharmaceuticals, plastics and crop protection products at state-of-the-art facilities. Well-known pharmaceutical companies such as Bayer Schering Pharma and Berlin-Chemie also have a long tradition of production in

Berlin alongside global medical engineering companies such as Biotronik. Siegfried Biologics is an expanding CMO for biopharmaceutical substances. Several small and medium-sized businesses in the fields of medical engineering and biotechnology form the entire value chain all the way up to production. The product range is quite broad and includes diagnostics, medications, vaccines, pacemakers, implants and devices designed for use in minimally invasive surgery. The first-class infrastructure found at regional technology parks also makes it possible for smaller companies to produce according to GMP standards.


Local production companies

- ALTANA Pharma (Nycomed Group)
- BASF
- Bayer Schering Pharma
- Berlin Chemie (Menarini Group)
- Biotronik
- Eckert & Ziegler
- MGB
- Siegfried Biologics
- Vanguard

Ideal conditions for production

- Well-trained technical personnel
- Attractive support by financial investment promotion (EU Target 1 and Target 2 areas)
- Favorable labor costs
- Professional assistance in business settlement
- Rapid business settlement
- Political support

Percentage of R&D personnel working in the manufacturing industry in 2003



Source: 10/2006 Stifterverband Wissenschaftsstatistik

Schwarzheide – BASF's Third Largest Production Facility in the World

Dr. Knabe, BASF has been in Schwarzheide since 1990. What was the major reason behind the decision to move here?

The decisive factor was the polyurethane chemistry already existing at the site. There were also former business contacts that were in place even before the fall of the Berlin Wall. We also used the opportunity to develop and expand facilities in the former East German states. Plus, Schwarzheide is a gateway to Eastern European markets.

How would you rate Brandenburg today as a production location on an international scale?

The region offers us clear advantages over other European production locations. We regularly measure the cost efficiency of our production sites based on an internal company benchmark. Production at our Brandenburg facility is very affordable and, on a European level, we produce here as cheaply as one could only in Spain. The main arguments in favor of the Berlin-Brandenburg region are the low-cost environment and the pool of well-trained professionals.

»Schwarzheide is a gateway to Eastern European markets.«

What markets does BASF Schwarzheide service?

We have a very clear concept within the BASF group. In principle, we produce where the market is. In 2006, Schwarzheide began production of our biodegradable plastic Ecoflex – a product development with great potential. Ecoflex is the basic material of Ecovio, a plastic based on renewable resources (PLA).

Ecoflex is processed further directly on the premises. What is your experience with respect to the settlement of middle-size partners?

Our cooperation with ZAB Brandenburg Economic Development Board, the regional business development agency, is very good. This is one of the definite strengths of the 13 settlement projects we've had here. The excellent investment support, contact coordination and relationships to public authorities – these are all definitely major arguments in favor of Schwarzheide. All the companies that have settled in the region are more than happy with the support they have received.

Two further examples from the field of industrial biotechnology are BIOPETROL Schwarzheide GmbH and BIOP Biopolymer Technologies, both of which process Ecoflex. Yet another decisive factor in favor of Schwarzheide as a production location was that everything goes faster than in other German federal states. Settlements such as these help to expand the value chain – an advantage for all involved.

»Production at our Brandenburg facility is very affordable and, on a European level, we produce here as cheaply as one could only in Spain.«



Dr. Volker Knabe
Chairman of the Management Board, BASF Schwarzheide GmbH
www.basf-schwarzheide.de



From left to right
BASF large scale production facility in Schwarzheide
Merete Medical produces implants and instruments in Luckenwalde and Berlin
Production of stent systems at Biotronik in Berlin

Strategic Advantages in Berlin-Brandenburg

Strategic location advantages in international comparison


Berlin-Brandenburg has clear business location advantages that continue to attract both national and international investors. The most decisive factors in the region's favor include its investment-friendly climate, attractive financing and support programs, a highly qualified workforce and the availability of low-cost office, lab and industrial space. The region also boasts state-of-the-art laboratory and office space in a network of science and technology parks. Life Sciences companies profit from the high concentration of internationally renowned research institutes, universities

and colleges. The region is home to over 50,000 scientists who represent a concentration of approximately 15% of Germany's scientific human resources. The cost of living, renting and real estate in the region lies significantly below that of other metropolitan regions. The vibrant city of Berlin and the charming Brandenburg landscape offer the highest quality of living for every taste and lifestyle. These strategic location advantages are reflected in the high number of new business settlements: 624 companies came to Berlin-Brandenburg between 2001 and 2005.

Company Satisfaction with the Business Location

Are you satisfied with your current business location?

- Quality of life
- Availability of qualified staff
- Wage levels




Source: Ernst & Young Study 2006

Labor Costs in Comparison

- Hourly wage
- Additional personnel costs

Costs per hour in manufacturing in 2005 in euro



Source: 32/2006 Deutscher Institutsverlag

»Berlin-Chemie in Berlin-Adlershof is one of the fastest growing companies in the research-based pharmaceutical industry in Germany. We obtain more than 50% of our sales in Eastern Europe. Berlin is a gateway between East and West, which makes it the ideal location for the ongoing positive development of Berlin-Chemie AG. In the past five years, we've been able to triple our sales and double our number of employees.«



Dr. Reinhard Uppenkamp
CEO Berlin-Chemie AG
www.berlin-chemie.de




Uwe de Buhr
Non-Executive Director LGC Ltd.
www.lgc.co.uk

»LGC is Europe’s leading provider of analytical services. We are active in the fields of forensics, chemistry, biochemistry, food chemistry and reference standards. After several other investments in Europe, we invested in facilities in Luckenwalde near Berlin, which marked the establishment of our first laboratories outside of England.

We continue to be very impressed by the optimal conditions found in the capital region. In particular, we have been encouraged to make further investments in Berlin and Brandenburg as a result of the availability of state-of-the-art laboratory facilities and highly qualified employees at internationally competitive rates. Our plans for further growth also profit from need-oriented financial support programs offered by the region.«

International Tax Burdens



Source: Forbes Tax Misery & Reform Index, German Federal Ministry of Finance 2006

Tax and Social Security Burden 2004

- Employee's Social Security Contribution
 - Employer's Social Security Contribution
 - Wealth Tax (France and Italy)
 - VAT
 - Highest Personal Income Tax
 - Corporate Earnings Tax
- * A further reduction to 12.5% is currently being discussed by the governing coalition in Germany
- ** Including the solidarity tax contribution (5.5%)

Where investment really pays

The Berlin-Brandenburg region offers the best conditions for financial aid available in Europe. Investment in Germany is supported via direct subsidies rather than tax breaks. Large-scale companies in the capital region receive up to 30% subsidies on investments, with small and medium-sized companies receiving up to 50%.

R & D projects are supported effectively by means of attractive state and federal programs. Companies also profit from support measures designed to promote the former East German states.

European Region and City of the Future – Germany 2006/2007

Eastern Germany was awarded first place as the »European Region of the Future – Germany« by the British magazine Foreign Direct Investment. At the same time, Berlin was awarded first place in the category »European City of the Future – Germany 2006/7.« FDI is a foreign investment journal and part of the Financial Times Group.

Each year it hands out awards to regions and cities with the best investment prospects for foreign investors. Participants are judged according to business potential, cost efficiency, profitability, human capital, infrastructure, overall quality of living as well as opportunities for financial support and subsidies.






Unique landscape design at Sanssouci Palace, the summer residence of Frederick the Great

A Great Place to Live

A cultural metropolis surrounded by inspiring nature

The capital region offers a wonderful mixture of urban lifestyle, culture, history and a beautiful natural environment. Berlin continues to hold a magnetic attraction and excitement for young and creative people, but there are also plenty of calm and quiet neighborhoods and much open space for recreation and relaxation. Potsdam, the state capital of Brandenburg, lies just outside the Berlin metropolitan area and combines the delightful charm of historical Prussian parks and gardens with modern city living and sophisticated residential housing. The region's many fascinating locations, parks and biospheres offer an ideal setting for a diverse recreational activities at the very heart of Europe's largest area of connected rivers and lakes.

This variety of urban and rural landscapes makes the region a great place to live for all types of lifestyles. Openness and tolerance characterize life in the region. People from more than 185 nations call Berlin-Brandenburg their home and enrich the culture and lifestyle of the region. Many new Berliners and Brandenburgers, as well as visitors from all over Germany and abroad, continue to be pleasantly surprised by the region's affordable cost of living. Whether it be rents and real estate prices, cultural opportunities or recreational activities – the price level is clearly well below that of other Western metropolitan areas.





Investing Made Easy

The region's two business development agencies, Berlin Partner GmbH and ZAB Brandenburg Economic Development Board, are the key contact partners for companies in Berlin and Brandenburg. They provide comprehensive support during your company's settlement in the region – professional, quick, with no red tape and free of charge.

- **Business Location** Facts and figures on the life science industry and the Berlin-Brandenburg economic region, www.businesslocationcenter.de/lifesciences
- **Real Estate and Facilities** Assistance in locating properties and sites for sale or rent
- **Financial Support and Subsidies** Expert advice on subsidies and financing opportunities
- **Qualified Personnel** Support in recruiting and training new staff
- **Contacts** to government agencies, banks, chambers of commerce, associations and business networks

Berlin Partner GmbH

Ludwig Erhard Haus | Fasanenstrasse 85 | 10623 Berlin

Contact: Carolin Clement

Head of Business Unit Life Sciences

T: +49 30 39980-230 | F: +49 30 39980-239

carolin.clement@berlin-partner.de

www.berlin-partner.de



Brandenburg Economic
Development Board

Brandenburg Economic Development Board (ZAB)

Steinstrasse 104–106 | 14480 Potsdam

Contact: Dr. Frauke Hein | Director Life Sciences

T: +49 331 660-3852 | F: +49 331 660-3144

frauke.hein@zab-brandenburg.de

www.invest-in-brandenburg.com



BioTOP Berlin-Brandenburg

The BioTOP Network supports companies in the fields of biotechnology, biomedicine and pharmaceuticals at the interface between science and business. BioTOP is your major contact partner for all matters relating to the biotech industry in the German capital region.

BioTOP Berlin-Brandenburg

Fasanenstrasse 85 | 10623 Berlin

Contact: Dr. Kai Bindseil | Director

T: +49 30 318622-11, F: +49 30 318622-22

biotop@biotop.de | www.biotop.de



TSBmedici

TSBmedici is an initiative of the Berlin Technology Foundation and is responsible for the region's development as a national center of expertise in the fields of medicine and medical technology. It brings together scientific research, hospitals, business and industry and also hosts individual network projects.

TSBmedici

Fasanenstrasse 85 | 10623 Berlin

Contact: Dr. Helmut Kunze | Director

T: +49 30 46302-547 | F: +49 30 46302-444

kunze@tsbmedici.de | www.tsbmedici.de



Health Capital Berlin-Brandenburg

The Health Capital Berlin-Brandenburg network coordinates the region's master plan in healthcare entitled »Berlin-Brandenburg Healthcare Region 2005–2015.« The network brings together players from the fields of medicine, science, healthcare and industry.

Health Capital Berlin-Brandenburg

TSB GmbH

Fasanenstrasse 85 | 10623 Berlin

Contact: Raphael Krüger | Managing Director

T: +49 30 46302-553 | F: +49 30 46302-444

info@healthcapital.de | www.healthcapital.de

IMPRINT



Publisher

Berlin Partner GmbH

Ludwig Erhard Haus | Fasanenstrasse 85 | 10623 Berlin

T: +49 30 20240-0, F: +49 30 20240-166

info@berlin-partner.de

www.berlin-partner.de

In cooperation with

Brandenburg Economic Development Board (ZAB),
BioTOP Berlin-Brandenburg and TSBmedici

Comissioned by

The Berlin State Senate Department for Economics, Technology and Women's Issues and the Brandenburg State Ministry of Economics

Content, Text

Almut Gebhard,

Strategische Kommunikation, Berlin

Design

Wollein&Co, Visual Concepts

www.leowol.com

Translation

The Hagedorn Group

www.hagedorn-group.com

Photography

Matthias Fischer, mfisher@macht.de

(except for the following):

© ALTANA Pharma GmbH: p. 17 left, p. 20

© BASF: p. 21 left | © B. Braun Melsungen: p. 7

right | © Berlin-Chemie: p. 7 left | © Berlin Partner

GmbH/FTB-Werbefotografie: p. 24 | © Berlin

Partner GmbH/diephotodesigner.de: p. 3 right

© Biotechnologiepark Luckenwalde GmbH:

p. 15 left | © Biotronik: p. 6, p. 21 right | © Celon

AG: p. 5 middle | © Brahms: p. 7 middle, p. 9 right

© Charité: p. 19 right | © DIFE: p. 11 left

© Eckert & Ziegler: p. 4, p. 5 left | © Epigenomics:

p. 5 right | © Helios Kliniken GmbH: p. 18, p. 19

left | © FMP/Stefan Meyer: p. 3 middle

© Fraunhofer IBMT: p. 3 left | © Jerini: p. 9 left

© Klinikum Ernst von Bergmann GmbH: p. 19

middle | © MDC/Uwe Eising: p. 15 middle

© metanomics: p. 11 middle | © Merete: p. 21

middle | © MicroDiscovery: p. 11 right | ©

Revotar AG: p. 8, p. 9 middle | © sanofi-aventis:

p. 17 right | © Bayer Schering Pharma: cover

page, p. 2, p. 16, p. 17 middle | © Scienion: p. 14

Production

M8 Labor für Gestaltung, Berlin
www.macht.de

The selection of companies presented is exemplary and makes no claim to be comprehensive.

This information contained here is supplied without liability and is subject to change.

© December 2006

